R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma
Lauren Westfall Veltri,Denái R. Milton,Ruby Delgado,Nina Shah,Krina K. Patel,Yago Nieto,Partow Kebriaei,Uday R. Popat,Simrit Parmar,Betul Oran,Stefan O. Ciurea,Chitra Hosing,Hans C. Lee,Elisabet E. Manasanch,Robert Z. Orlowski,Elizabeth J. Shpall,Richard E. Champlin,Muzaffar H. Qazilbash,Qaiser Bashir +18 more
TL;DR: Patients who are refractory to both proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) and the role of autologous hematopoietic stem cell transplantation in this population is limited.
Journal ArticleDOI
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
Ola Khorshid,E de Meis,Thomas G. Martin,Roy B. Jones,Elizabeth J. Shpall,Yago Nieto,Issa F. Khouri,Munir Shahjahan,James Gajewski,Sergio Giralt,Richard E. Champlin,M. de Lima +11 more
TL;DR: Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cells transplant.
Book ChapterDOI
Bone marrow transplantation for aplastic anemia: recent advances and comparisons with alternative therapies.
TL;DR: The prognosis of patients with severe aplastic anemia is grave with supportive care alone; approximately half die from bleeding or infection within 3–6 months, and less than 20% have hematologic recovery and prolonged survival.
Journal ArticleDOI
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis
M. Korbling,Sergio Giralt,Issa F. Khouri,Nadeem Q. Mirza,M. Donato,Paolo Anderlini,H. Fischer,Michael Andreeff,John McMannis,Richard E. Champlin +9 more
TL;DR: In this paper, the authors compared the yield of CD3+, CD3+4+6+8+16+ and CD34+ cells contained in apheresis products from 61 consecutive non-cytokine treated, human leukocyte antigen (HLA)-matched donors for lymphocyte collection with the corresponding APheresis-derived cell yield from 112 consecutive, HLA-matched donors who received recombinant human granulocyte colony stimulating factor (rhG-CSF, filgrastim) 6 μg/kg every 12 hours until cell collection was completed